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Abstract
Background: Pulmonary thromboembolism (PTE) is a common diagnosis and a leading cause of
cardiovascular morbidity and mortality. A growing literature has associated PE with systemic inflammation,
and global hyper-coagulability, which contribute to lung remodeling and clot recurrence. The source and
mechanism of inflammation remains unstudied. In humans, inhibition of cholesterol synthesis with statins
decreases biomarkers of inflammation. We test the differential effect of pulmonary vascular occlusion during
mild and severe pulmonary embolism on the lung transcriptome.
Methods: Experimental PE was induced in adult male rats by injection of 25 micron polystyrene microspheres
into the jugular vein. The effect of Mild PE, (2-h right ventricular systolic pressure [RVSP] normal, 18-h RVSP
44 mmHg) and Severe PE (2-h RVSP > 50 mmHg; 18-h RVSP 44 mmHg) on lungs was assessed by measuring
transcriptome-wide changes in gene expression by DNA microarrays.
Results: Severe PE was associated with a large change in lung gene expression and in the expression of
KEGG pathways and other gene functional annotation groups. Mild PE was also associated with a large
number of significant changes in gene expression and in the expression of KEGG pathways and gene
functional annotation groups, even after only 2 h of PE. Up-regulated pathways included increased
adipocytokine, chemokine and cytokine signaling as well as cholesterol synthesis.
Conclusions: Mild PE without acute pulmonary hypertension (PH) increased lung gene expression of
inflammatory pathways, including increased cholesterol synthesis. These data indicate that even mild
persistent pulmonary vascular occlusion is capable of inciting an inflammatory response from the lung. These
data imply the detrimental effect of unresolved pulmonary obstruction from PE.
Keywords: Lung, Pulmonary hypertension, Inflammation, Microarray, GeneSifter, DAVID, Fibrinolysis,
Thrombolysis
Background
Pulmonary embolism (PE) is a common and potentially le-
thal disease occurring in about 600,000 patients each year
in the U.S., leading to as many as 60,000 deaths [1–5].
The most common form of PE is pulmonary thrombo-
embolism (PTE), which results when blood clots, often
formed in the deep vasculature of the legs, detach and enter
the venous circulation. Circulating clots pass through the
right heart and enter the lungs via the pulmonary artery,
eventually lodging within the pulmonary vascular tree caus-
ing varying degree of pulmonary vascular occlusion and in-
creased pulmonary vascular resistance. PE results in both
acute and chronic sequelae. Acute PE causes a sudden in-
crease in RVSP and acute PH, leading to right ventricular
(RV) damage and dysfunction. A small subset of patients
with unresolved PE go on to develop pulmonary vascular
remodeling and RV hypertrophy which develops over time
to produce chronic thromboembolic pulmonary hyperten-
sion (CTEPH) [6]. A hallmark of CTEPH includes persist-
ent pulmonary vascular occlusion, and a widespread
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inflammatory response [7–11]. Increased lung inflamma-
tion has been implicated as a mechanism of reduced angio-
genesis, and for increased hyper-coagulability, leading to
recurrent PE [10, 12, 13]. Recurrent PE is a major risk fac-
tor for CTEPH development [8, 14]. Potential causes of in-
flammation include cells and molecules liberated by
clots themselves [15], direct interaction of fibrin and
the vessel wall [16], and the effect of shear on the
vessel wall and platelets resulting in microparticle for-
mation [9, 17]. Pulmonary vascular occlusion, with
deprivation of blood flow to the lung also triggers a
brisk inflammatory response [18].
We have previously described a rat model of PE induced
by injection of 25 micron polystyrene microspheres into
the right jugular vein [18–25]. Although microsphere PE
lacks many of the characteristics of PTE such as platelet
activation and thrombosis, it does faithfully produce the
desired features of pulmonary ischemia and, at high doses,
pulmonary hypertension. Rat lungs receiving doses of mi-
crospheres that produced acute PH (Severe PE, right ven-
tricular systolic pressure [RVSP] ≈50 mmHg and 10 %
animal mortality) had a >5-fold increase in recoverable
bronchoalveolar lavage (BAL) neutrophils compared to
control rats, indicating a neutrophilic inflammation [18].
Strong neutrophil chemotactic activity was measured in
isolated alveolar lavage fluid and this activity was inhibited
greater >50 % by treatment with anti-rat CXCL1 antibody.
Rat lungs embolized with a lower dose of microspheres
(Mild PE, normal RVSP 2-h post-PE and zero mortality),
did not show neutrophil or protein accumulation in
alveoli, but did show elevated expression of the che-
mokine genes CXCL1, CXCL2, CXCL3 and CCL2
[18]. These latter data led to a realization that Mild
PE was sufficient to induce a pro-inflammatory envir-
onment within lung tissues, at least at the level of
gene expression, and that lungs might be more sensi-
tive to Mild PE than hearts. In this present study, the
transcriptome-wide effect of Mild PE and Severe PE
on rat lungs has been examined using DNA microar-
rays. The primary question was to answer the ques-
tion whether whether Mild PE, which has been
observed to be benign to RV dysfunction and inflam-
mation [20–23], had a disproportionately worse effect
on lungs.
Methods
Animal care
Experiments were done on male Sprague–Dawley rats
weighing between 375 and 400 g. All experiments were
conducted in accordance with the NIH Guide For the Care
and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee (IACUC) of
Carolinas Medical Center, Charlotte NC (4-02-01A and 11-
00-01A). Prior to use, rats had ad libitum access to food
and water.
Pulmonary embolism model
PE was induced in rats by intra-jugular vein injection of
25-micron polystyrene microsphere beads (Duke Scientific
#7525A, Palo Alto CA) as previously published [18–25].
Anesthetized rats were injected with either 1.3 or 2.0
million microspheres/100 g body weight to produce Mild
PE and Severe PE, respectively. Control rats were injected
with 0.15 ml/100 g of 0.01 % Tween 20 (the resuspension
vehicle for microspheres), which was equivalent in volume
to the Severe PE dose of microspheres. These treatment
groups are referred to as “Vehicle” or “Veh”.
Microarray analyses
Lung tissue samples from whole right lung lobes used
for this study are the same as those collected for a pre-
viously published study [18]. In that study, Mild PE
produced 2-h RVSP that was not statistically significant
from RVSP in control rats (mean 39 mmHg for Mild
PE verses mean 32 mmHg for controls, p > 0.05) while
2-h Severe PE caused elevation of RVSP to >50 mmHg
[18]. Lungs were also collected from rats after 18-h of
PE but RVSP was not measured. In subsequent studies,
Mild PE was shown to cause a rise in 18-h RVSP to
mean 44+/−1.3 mmHg (p < 0.05 relative to vehicle)
while the RVSP in 18-h Severe PE was shown to fall
from a peak of >50 mmHg to 44+/−0.9 mmHg [20, 22].
We have consistently concluded that Severe PE is asso-
ciated with PH for the full time course of 2–18 h while
Mild PE consistently shows PH only at the 18-h time.
RNA was prepared from crushed whole right lung
tissue which had been stored at −80 °C using the acid-
phenol guanidinium isothiocyanate method of Chomc-
zynski and Sacchi [26] followed by a second round of
purification on RNeasy columns (Qiagen, Germantown,
MD). Total lung RNA was prepared for microarray
hybridization by standard Affymetrix procedures as
previously described and checked for RNA integrity on
agarose gels prior to use [23, 24]. Fragmented cRNAs
were then hybridized to Affymetrix Rat Genome 230
v2.0 microarrays, washed and fluorescently stained in
the Affymetrix Fluidics Station 400 using Affymetrix
procedures. Each array was scanned twice by an Agilent
Gene Array Scanner G2500A (Agilent Technologies,
Palo Alto, CA).
Microarray data were initially analyzed with Gene-
Sifter web-based software (Geospiza, Seattle, WA;
(http://www.genesifter.net). Affymetrix “.cel” files were
up-loaded to the GeneSifter web site using GC-RMA
normalization into “Pair-wise” and “Project” folders
for access to t-test and ANOVA statistical methods,
respectively. A 2-way ANOVA was used to initially
Zagorski and Kline Respiratory Research  (2016) 17:86 Page 2 of 13
compare the six treatment groups using time as the
first factor (2-h and 18-h) and microsphere dose as
the second factor (Vehicle, Mild PE, Severe PE). A
1.5-fold expression difference threshold and Benjamini
and Hochberg correction for false discovery (p < 0.05)
was used as “pass” criteria. Genes that passed any one
of the criteria of time, dose or interaction were ac-
cepted. The 6 sample groups used in the 2-way
ANOVA were then subjected to hierarchical clustering
to determine the similarities of the groups using the
GeneSifter “Cluster” function.
Separate 1-way ANOVAs were used to compare the
three 2-h treatment groups and three 18-h treatment
groups for genes with related expression patterns based
on the factor of microsphere dose (1.5-fold expression
difference threshold relative to 2-h vehicle and 18-h ve-
hicle groups as controls, respectively, Benjamini and
Hochberg correction for false discovery, p < 0.05). Clus-
tering of genes within the 2-h and 18-h ANOVAs were
done using the GeneSifter PAM function (Partitioning
Around Medoids) with a user-defined 12-cluster output.
PAM searches a gene list for groups of genes (clusters)
within the list that have a characteristic that is shared by
all genes within that group but different from genes
within other groups (hence, “clustering”). The character-
istic used by GeneSifter was the pattern of expression
each gene showed for the Vehicle, Mild PE and Severe
PE treatments. GeneSifter allowed the user to specify the
number of clusters that the entire gene list would be
sorted into. For the analyses in Figs. 2 and 3, the 2-h
and 18-h gene lists were sorted into 12 clusters. This
number of clusters was determined empirically as the
fewest number of clusters which yielded Mild PE-
selective and Severe PE-selective expression patterns for
the 2-h ANOVA data. These patterns were defined as
expression patterns in which the change in expression
from control was maximal between Vehcile and Mild PE
and between Mild PE and Severe PE, respectively.
Pairwise comparison of treatment groups was done
with GeneSifter using 2-sided unpaired t-tests with a
1.5-fold expression difference threshold relative to ve-
hicle groups and with Benjamini and Hochberg correc-
tion for false discovery, p < 0.05.
Excel spreadsheet exports of 2-h and 18-h GeneSifter t-
tests were used to prepare gene lists for further analysis
using DAVID (Database for Annotation, Visualization and
Integrated Discovery; http://david.abcc.ncifcrf.gov; [27, 28]).
Lists of official gene symbols were first separated into new
lists of up-regulated and down-regulated probesets from
the pairwise t-test spreadsheets in Additional file 2A-C (2-h
data) and 2D-F (18-h data). The six possible combinations
of treatment times and PE doses were examined: 2-h and
18-h Mild PE verses Vehicle, Severe PE verses Vehicle, and
Mild PE verses Severe PE expression. “UP” and “DOWN”
lists of official gene symbols were then separately pasted
into the search input in DAVID. DAVID analyzes gene lists
and identifies all of the annotations that are attributed to
each gene in the list. Gene annotations are categories of
gene function, protein structural features, biochemical
pathways and other shared gene or protein properties that
are manually given by database curators to all genes and
proteins. DAVID then produces several types of output that
group the members of the input gene list into these annota-
tions and determines statistical significance by comparing
the number of genes from the submitted gene list that are
present in each annotation with the total number of genes
that are in the annotation (this is an “enrichment calcula-
tion”). Functional annotation charts were generated using
DAVID default stringency settings (“moderate”). Each
downloaded chart was a spreadsheet containing a list of all
known annotations that contained at least one gene from
the input list of PE genes from the t-test and the probability
that the input list of PE genes was enriched in genes of that
annotation. Final annotation charts were then assembled by
merging the UP- and DOWN-enriched annotations for
each combination of PE dose and time. These charts were
then reduced in complexity by discarding annotation terms
that were not significantly enriched in the input PE gene list
(t-test, Benjamini and Hochberg values >0.05) and by
discarding all Gene Ontology (GO) terms in the DAVID
output regardless of statistical significance. GO term anno-
tations greatly increased the length of the annotation lists
but have limited investigative value in the opinion of the
authors. All microarray data have been deposited in the
NIH/NCBI “GEO” database (http://www.ncbi.nlm.nih.gov/
projects/geo; GEO accession number GSE13535).
Results
Six-group ANOVA, gene clustering, and pair-wise t-tests
of treatment groups
A comprehensive summary of all microarray data was first
generated by comparing the six treatment groups (Mild PE,
Severe PE and Vehicle each at 2-h and 18-h) in this study
using a 2-way ANOVA, using the GeneSifter software suite
(1.5-fold expression change minimum, Benjamini and
Hochberg correction for false discovery, p < 0.05). The data
is contained in Additional file 1 and shows that 8075 Affy-
metrix probesets passed the ANOVA for at least one of the
tests (Factor 1, time; Factor 2, dose; interaction). The data
from the ANOVA was then subjected to hierarchical clus-
tering using GeneSifter to define the relationships between
the six treatment groups. This output is summarized in the
dendrogram shown in Fig. 1. The three 2-h groups were
closely associated, as were the 18-h Mild PE and 18-h
Severe PE groups while the 18-h vehicle clustered with the
2-h vehicle.
The six groups were also compared pair-wise (t-test,
1.5-fold expression change minimum, Benjamini and
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Hochberg correction, p < 0.05). These results are summa-
rized on the left side of Fig. 1, and are available as spread-
sheets in Additional file 2A-C and D-F (2-h groups and
18-h groups, respectively). For the Mild PE treatment
groups there was a 4.43-fold increase in the number of
significantly altered probesets between 2 and 18 h after PE
(496 verses 2195). Similarly, for the Severe PE treatment
groups there was 22.9-fold increase in the number of sig-
nificantly altered probesets between 2 and 18 h after PE
(177 verses 4048). Comparison of the Mild PE and Severe
PE treatment groups at the same times revealed that the
18 h Severe PE group had 1.84-fold more altered probe-
sets than the 18 h Mild PE group (4048 verses 2195), while
the Severe PE group had fewer altered probesets at 2 h
than the Mild PE group (177 verses 496). In a separate
comparison of the two vehicle control groups (2 h and
18 h), only five probesets were significantly different, three
of which were annotated in the GeneSifter database as
“transcribed loci” only (data not shown). Taken together,
these data indicated that although Severe PE produced a
larger change in gene expression than Mild PE, Mild PE
was sufficient to produce a robust change in lung gene
expression.
Separate analyses of 2-h and 18-h treatment groups
The responses of rats to mild PE and Severe PE were com-
pared using separate 1-way ANOVAs of the 2-h and 18-h
treatments with GeneSifter (expression difference thresh-
old >1.5-fold, t-test <0.05, Benjamini and Hochberg). For
the three 2-h treatment groups 775 probesets were altered
in expression relative to the 2-h vehicle control, while 4360
probesets were altered in the 18-h groups relative to the
18-h vehicle control (1.5-fold expression difference thresh-
old, t-test <0.05, Benjamini and Hochberg). The altered
probesets in the 2-h and 18-h ANOVAs were then clus-
tered into similar expression patterns with GeneSifter
using the PAM function (Partitioning Around Medoids)
with a user-designated output of 12 clusters for each
ANOVA. These data are presented in Figs. 2 and 3 for 2-h
and 18-h treatment groups, respectively.
The PAM-clustering of the 2-h ANOVA data is shown in
Fig. 2, and clearly indicates three distinct patterns. 5 of 12
clusters had a “Mild PE-selective” pattern (clusters 3, 6, 8,
10 and 12). Probesets in these clusters had greater changes
in expression between the vehicle and Mild PE samples
than between the Mild PE and Severe PE samples. 2 of 12
clusters had a “Severe PE-selective” pattern (clusters 4 and
5). Probesets in these clusters had greater changes in ex-
pression between the Mild PE and Severe PE samples than
between the vehicle and Mild PE samples. Curiously, 4 of
12 clusters had a Mild PE-specific pattern (clusters 1, 2, 9
and 11). Probesets in these clusters had peak increases or
decreases in expression between the Vehicle and Mild PE
treatments but minimal change in expression between the
Mild PE ad Severe PE treatments. The magnitudes of the
Mild PE expression changes in two of these clusters were
within a single log2 increment of the vehicle and Severe PE
groups (clusters 1 and 2) while the magnitudes of the Mild
PE expression changes in the other two clusters (9 and 11)
reached 4 log2 increments of the vehicle and Severe PE
groups. These four clusters, and clusters 9 and 11 in par-
ticular, suggest that there were opposing signals for up- and
down-regulation of gene expression in the Mild PE and
Severe PE groups.
The PAM-clustering of the 18-h ANOVA data is shown
in Fig. 3. Clustering of the 18-h treatment groups resulted
in fewer clusters with obvious Mild PE-selective and Severe
PE-selective gene expression than observed for the 2-h
ANOVA. A plurality of clusters had “non-selective” pat-
terns of gene expression (2, 3, 7, 8 and 10). Probesets in
these clusters had nearly identical changes in expression
between the vehicle and Mild PE samples and Mild PE and
Severe PE samples. 4 of 12 clusters had a Mild PE-selective
pattern (clusters 4, 5, 11 and 12) while two clusters (1 and
9) were intermediate between Mild PE-selective and non-
selective. In contrast to the 2-h treatments, none of the
clusters were indicative of Severe PE-selective expression.
Enrichment of PE genes in functional annotations
Gene expression data from the pairwise t-tests of Mild PE
and Severe PE treatment groups (Additional file 2A – F)
were examined for significant enrichment of PE-altered
probesets present in database annotations using DAVID
Fig. 1 Hierarchical clustering of six treatment groups and results of
pair-wise t-tests. Expression data from the six treatment groups were
first compared by 2-way ANOVA using PE time as factor-1 and
microsphere dose as factor-2. Relationships among the six treat-
ments were determined using GeneSifters hierarchical clustering
function applied to the 8075 Affymetrix probesets that passed the 2-
way ANOVA. The separation of the six treatment groups on the
dendrogram is based on relative Euclidean distance. Numerical data
superimposed on the dendrogram are the results of pair-wise t-tests
between the treatment groups
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web-based software (KEGG pathways, INTERPRO,
SMART and SP_PIR database terms; GO terms excluded).
Tables 1 and 2 summarize the functional annotations
enriched in the Mild PE and Severe PE treatment groups,
respectively.
Functional annotations enriched in the Mild PE treat-
ment groups relative to time-matched vehicle controls are
shown in Table 1. Annotations unique to Mild PE treat-
ment groups are highlighted with bold font and italics
while annotations common to Low- and Severe PE are in
standard font. Blank cells in the data indicate that an an-
notation was not significantly over-represented at a par-
ticular time and treatment combination. At the 2-h time,
the majority of annotations (10 of 21 total annotations)
were unique to Mild PE, while a minority (11 of 21) were
shared with the Severe PE 2-h group (Table 2). Con-
versely, at 18-h only 5 of 22 total annotations were unique
to Mild PE (23 %) while 17 of 22 (77 %) were shared with
the Severe PE group (Table 2). These data support a dis-
tinct mechanistic difference between Mild and Severe PE.
If Mild PE were merely a less robust manifestation of Se-
vere PE, all annotations present during Mild PE would be
expected to be present during Severe PE.
Functional annotations enriched in the Severe PE treat-
ment groups relative to time-matched vehicle controls are
shown in Table 2. Annotations unique to Severe PE treat-
ment groups are highlighted with bold font and italics
while annotations common to Low PE and Severe PE are
Fig. 2 Clustering of 2-h treatment groups. Expression data from the three 2-h treatment groups (Vehicle, Mild PE, Severe PE; x-axis labels 1, 2, 3,
respectively) were clustered using the PAM function of GeneSifter. A 12-cluster output was manually specified. Expression relative to Vehicle
groups is provided on y-axes and is log2 transformed. The labels “Mild-PE” and “Severe-PE” are used to refer to patterns of expression that are primarily
altered between the Vehicle and Mild PE groups or Mild PE and Severe PE groups, respectively
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in standard font. It is noteworthy that the data in Table 2
showed a distinct separation of annotations between the
two times. Of the 57 total annotations listed in the table
only one, “SP-PIR chemotaxis”, was present at both times.
The remaining 56 annotations were present at only one of
the time points. This pattern was not seen with the Low
PE data in Table 1 in which a greater proportion of the
total annotations were present at both times. Together,
these data suggest a rapid “progression” of the Severe PE
condition at the transcriptional level compared to a more
gradual transcriptional “progression” for Mild PE.
Annotations unique to mild PE
Further examination of the Mild PE expression data in
Table 2 revealed that 13 of 35 total annotations were
unique to Mild PE. Several of these unique annotations in-
volved pro-inflammatory KEGG pathways or protein
families. The KEGG pathways were: rno04920 “adipocyto-
kine signaling”, rno04062 “chemokine signaling”, rno04060
“cytokine-cytokine receptor”, and rno04620 “Toll-like re-
ceptor signaling”. Rno04010 “MAPK signaling pathway”
was also present, but this pathway intersects with diverse
cellular processes beside inflammation. The Interpro anno-
tation IPR000827 “small cytokine C-C” and Protein Infor-
mation Resource annotation PIRSF001950 “small inducible
chemokine” were also present. The presence of gene anno-
tations unique to the 2-h Mild PE treatment, which shares
little physiological similarity with Severe PE, continue to
support a conclusion that Mild PE and Severe PE may be
mechanistically dissimilar at the transcriptional level.
Are mild PE and severe PE related?
The possible similarities between the 18-h Mild PE and
2-h Severe PE found in Tables 1 and 2 prompted a direct
Fig. 3 Clustering of 18-h treatment groups. Expression data from the three 18-h treatment groups (Vehicle, Mild PE, Severe PE; x-axis labels 1, 2, 3,
respectively) were clustered as for Fig. 2
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comparison between these two treatment groups. These
data are presented in Table 3. However, only 6 of 36 an-
notations present in either of the two treatments were
shared by both: SP-PIR chemotaxis, SP_PIR cytokine,
SP_PIR “inflammatory response”, rno04621 “NOD-like
receptor signaling pathway”, SM00199 “SCY” and
IPR001811 “small chemokine interleukin-8-like”. The
remaining 31 annotations which were enriched in either
Table 1 DAVID Functional Annotation Charts, 2-h and 18-h Mild PE verses Vehicle
Category Term a2-h Mild-PE vs. Vehicle 18-h Mild-PE vs. Vehicle
Ct % Dir Fold B&H Ct % Dir Fold B&H
SP_PIR acetylation 78 14.03 UP 1.51 0.009
rno04920 Adipocytokine signaling pathway 6 2.93 UP 7.47 0.015
rno00970 Aminoacyl-tRNA biosynthesis 8 1.44 UP 5.56 0.017
rno04210 Apoptosis 6 2.93 UP 5.89 0.028
rno00330 Arginine and proline metabolism 9 1.62 UP 4.72 0.015
rno05217 Basal cell carcinoma 10 1.11 D 4.28 0.016
IPR004827 Basic-leucine zipper (bZIP) transcription factor 7 3.41 UP 11.97 0.003
SM00338 BRLZ 7 3.41 UP 10.46 0.001
rno04062 Chemokine signaling pathway 12 5.85 UP 5.85 0.000 20 3.60 UP 3.25 0.001
SP_PIR chemotaxis 9 4.39 UP 22.67 0.000 11 1.98 UP 10.30 0.000
rno04610 Complement and coagulation cascades 10 1.80 UP 3.97 0.019
SP_PIR cytokine 11 5.37 UP 9.02 0.000 16 2.88 UP 4.88 0.000
rno04060 Cytokine-cytokine receptor interaction 10 4.88 UP 4.24 0.008 23 4.14 UP 3.25 0.000
rno04623 Cytosolic DNA-sensing pathway 5 2.44 UP 9.07 0.024
SP_PIR disulfide bond 76 13.67 UP 1.43 0.044
SP_PIR dna-binding 20 9.76 UP 2.43 0.023
rno00982 Drug metabolism 13 1.45 D 3.94 0.004
rno04512 ECM-receptor interaction 14 1.56 D 3.77 0.005
PIRSF001719 fos transforming protein 4 1.95 UP 59.84 0.001
IPR000837 Fos transforming protein 4 1.95 UP 40.08 0.010
rno00480 Glutathione metabolism 9 1.00 D 3.93 0.042
rno04640 Hematopoietic cell lineage 6 2.93 UP 6.42 0.022
rno00340 Histidine metabolism 7 0.78 D 6.37 0.017
SP_PIR inflammatory response 8 3.90 UP 16.01 0.000 11 1.98 UP 8.18 0.000
rno04010 MAPK signaling pathway 10 4.88 UP 3.14 0.029
rno00980 Metabolism of xenobiotics by cytochrome P450 13 1.45 D 4.73 0.002
rno04621 NOD-like receptor signaling pathway 9 4.39 UP 12.11 0.000 10 1.80 UP 4.49 0.016
SP_PIR oxidoreductase 42 4.68 D 1.89 0.034
rno05020 Prion diseases 7 1.26 UP 5.56 0.028
SP_PIR ribosome biogenesis 7 1.26 UP 8.85 0.007
SM00199 SCY 8 3.90 UP 16.89 0.000 10 1.80 UP 8.76 0.000
IPR000827 Small chemokine, C-C group, conserved site 4 1.95 UP 25.50 0.033
IPR001811 Small chemokine, interleukin-8-like 8 3.90 UP 19.35 0.000 10 1.80 UP 8.70 0.001
PIRSF001950 small inducible chemokine, C/CC types 5 2.44 UP 24.93 0.001
rno04620 Toll-like receptor signaling pathway 9 4.39 UP 8.34 0.000
Functional annotations significantly over-represented in the lists of up-regulated and down-regulated genes during 2-h and 18-h Low-PE. Annotations unique to Low-PE
are highlighted in bold italics; annotations common to Low-PE and High-PE (Table 2) are in standard font. Key: “Ct.”, number genes from a GeneSifter pairwise t-test result
(Additional file 3A-C) that were present in the functional annotation indicated; “%”, percent of genes contained within a list that were present in an annotation; “Dir, UP”,
annotations that were identified by DAVID when up-regulated genes were used as the search query; “Dir, D”, annotations that were identified by DAVID when down-
regulated genes were used as the search query. “Fold”, expression relative to vehicle group; B&H, value of Benjamini and Hochberg adjustment for false discovery following
t-test. aNo 2-h DOWN annotations meet B&H < 0.05
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Table 2 DAVID Functional Annotation Charts, 2-h and 18-h Severe PE verses Vehicle
Category Term a2-h Severe PE verses Vehicle 18-h Severe PE verses Vehicle
Ct % Dir Fold B&H Ct % Dir Fold B&H
SP_PIR acetylation 183 17.72 UP 1.86 0.000
SP_PIR activator 7 7.29 UP 5.58 0.025
SP_PIR acute phase 7 0.68 UP 4.89 0.047
rno00520 Amino sugar and nucleotide
sugar metabolism
12 1.16 UP 4.37 0.002
rno00970 Aminoacyl-tRNA biosynthesis 12 1.16 UP 4.70 0.002
SP_PIR Aminoacyl-tRNA synthetase 10 0.97 UP 5.11 0.003
rno00330 Arginine and proline metabolism 11 1.06 UP 3.25 0.046
rno05412 Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
15 0.96 D 2.56 0.040
rno05217 Basal cell carcinoma 12 0.77 D 2.97 0.036
IPR011700 Basic leucine zipper 4 4.17 UP 41.80 0.004
IPR004827 Basic-leucine zipper (bZIP) transcription factor 8 8.33 UP 28.54 0.000
SM00338 BRLZ 8 8.33 UP 20.66 0.000
IPR011616 bZIP transcription factor, bZIP-1 4 4.17 UP 25.44 0.015
SP_PIR Chaperone 18 1.74 UP 2.78 0.006
SP_PIR chemotaxis 4 4.17 UP 20.78 0.025 9 0.87 UP 4.43 0.016
SP_PIR Cholesterol biosynthesis 9 0.87 UP 7.47 0.000
rno04610 Complement and coagulation cascades 17 1.65 UP 3.80 0.000
SP_PIR cytokine 9 9.38 UP 15.21 0.000
SP_PIR DNA binding 6 6.25 UP 7.38 0.028
SP_PIR dna-binding 15 15.63 UP 3.75 0.002
UP_SEQ DNA-binding region: Basic motif 10 10.42 UP 15.44 0.000
UP_SEQ domain: Leucine-zipper 9 9.38 UP 19.96 0.000
rno00982 Drug metabolism 20 1.28 D 3.51 0.000
rno04512 ECM-receptor interaction 17 1.09 D 2.65 0.020
SM00180 EGF_Lam 9 0.58 D 5.44 0.020
IPR002049 EGF-like, laminin 9 0.58 D 5.98 0.026
SP_PIR endoplasmic reticulum 63 6.10 UP 2.04 0.000
PIRSF001719 fos transforming protein 4 4.17 UP 109.2 0.000
IPR000837 Fos transforming protein 4 4.17 UP 83.59 0.001
rno00480 Glutathione metabolism 12 0.77 D 3.03 0.041
rno00340 Histidine metabolism 9 0.58 D 4.73 0.019
SP_PIR inflammatory response 4 4.17 UP 16.51 0.027 13 1.26 UP 5.08 0.000
SP_PIR Initiation factor 12 1.16 UP 4.55 0.002
SP_PIR Isomerase 17 1.65 UP 3.14 0.003
SP_PIR lipid synthesis 19 1.84 UP 3.82 0.000
rno00980 Metabolism of xenobiotics by cyt. P450 18 1.15 D 3.79 0.000
UP_SEQ mutagenesis site 59 3.77 D 1.75 0.042
rno04621 NOD-like receptor signaling pathway 5 5.21 UP 12.52 0.034
SP_PIR nucleotide-binding 99 9.58 UP 1.36 0.024
SP_PIR nucleus 22 22.92 UP 2.01 0.026
SP_PIR phosphoprotein ## 27.49 UP 1.24 0.000
IPR011993 Pleckstrin homology-type 32 2.05 D 2.27 0.027
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the 2-h Severe PE or 18-h Mild PE groups were confined
to one or the other group. These data refute a similarity
between early Severe PE and late Mild PE.
Steroid synthesis during 18-h severe PE
Three annotations were detected in the 18-h Severe PE
gene lists which were associated with steroid and/or sterol
biosynthesis. A total of 16 unique genes were contained
within these annotations. These data are presented in
Table 4. Most of these genes were contained on the KEGG
pathway rno00100 (R. norvegicus Steroid Biosynthesis;
http://www.kegg.jp/kegg-bin/show_pathway?rno00100).
This pathway terminates with several branches but all of
the genes induced by Severe PE were located on the
branch terminating with cholesterol.
HMGCR, HMGCS1 and IDI1 function upstream of
rno00100 and were found on the KEGG pathway
rno00900 (R. norvegicus Terpenoid Backbone Biosyn-
thesis; http://www.kegg.jp/kegg-bin/show_pathway?
rno00900). This pathway begins with acetyl-CoA, pro-
ceeds through 3-hydroxy-3-methyglutaryl-CoA (HMG-
CoA), mevalonate, isopentenyl-diphosphate and farnesyl-
diphosphate, which is the metabolic intermediate that feeds
KEGG Pathway rno00100.
Discussion
Microsphere-induced PE caused profound changes in
gene expression in rat lungs even when RVSP was lower
than typically considered clinically relevant. These data
contrast sharply with previous results on the effects of
this same PE model on transcriptional changes in hearts
[23]. In this latter study, Zagorski et al. demonstrated an
almost obligatory requirement for PH to cause altered
gene expression in RV tissues [23]. In particular, 2-h
Mild PE resulted in no statistically significant transcrip-
tional changes in RVs and few changes after 18-h. The
effect of Mild PE on gene expression in lung tissue re-
ported here was much more dramatic. 2-h of Mild PE
with minimal PH was sufficient to cause numerous
changes in gene expression and statistically significant
alteration in at least 21 expression pathways or other
gene group annotations. Examination of the annotations
enriched in the 2-h Mild PE “UP” gene expression data
revealed several pro-inflammatory annotation terms.
The abundance of pro-inflammatory annotations
enriched in 2-h Mild PE samples indicates that lungs ex-
posed to even mild PE with minimal PH rapidly enter
into a pro-inflammatory state. This data supports a con-
clusion that even mild PE has the potential to initiate
damage to lung tissues. This is in stark contrast to the
total lack of right ventricular inflammation seen in the
microsphere model of Mild PE [19–25].
Mild and Severe PE are hemodynamically distinct at
2-h post-PE, with only the latter having PH. This brings
into question the stimuli imparted on lungs with 2-h
Mild PE which are responsible for the large changes in
gene expression. The most likely explanation is ischemia,
which is often considered synonymous with hypoxia.
However, ischemia resulting from occlusion of the pul-
monary vasculature is unique, since the pulmonary ar-
tery circulates oxygen-poor and nutrient-depleted blood
derived from the venous circulation. In essence, even
normal circulation through the pulmonary artery is hyp-
oxic, and occluded flow through the pulmonary artery
Table 2 DAVID Functional Annotation Charts, 2-h and 18-h Severe PE verses Vehicle (Continued)
SP_PIR protein biosynthesis 22 2.13 UP 2.04 0.049
SP_PIR protein transport 34 3.29 UP 1.87 0.016
SP_PIR Redox-active center 10 0.97 UP 4.74 0.005
SP_PIR ribosome biogenesis 8 0.77 UP 5.31 0.014
SP_PIR rna-binding 33 3.19 UP 2.16 0.002
SM00360 RRM 21 2.03 UP 2.69 0.015
SM00199 SCY 5 5.21 UP 18.26 0.003
IPR001811 Small chemokine, interleukin-8-like 5 5.21 UP 25.22 0.002
SP_PIR Steroid biosynthesis 13 1.26 UP 5.08 0.000
rno00100 Steroid biosynthesis 9 0.87 UP 8.29 0.001
SP_PIR sterol biosynthesis 11 1.06 UP 7.31 0.000
SP_PIR Transcription 14 14.58 UP 3.23 0.009
SP_PIR transcription regulation 14 14.58 UP 3.48 0.006
SP_PIR translocation 11 1.06 UP 3.75 0.014
rno00350 Tyrosine metabolism 10 0.64 D 3.71 0.032
Functional annotations significantly over-represented in the lists of up-regulated and down- regulated genes during 2-h and 18-h High-PE. Annotations unique to
High-PE are highlighted in bold italics; annotations common to High-PE and Low-PE (Table 1) are in standard font. All other keys are the same as
in Table 1. aNo 2-h DOWN annotations meet B&H < 0.05
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has no effect on oxygenation of lung tissue, which is
dependent on the separate bronchial circulation. Fur-
thermore, lung tissue is continuously exposed to atmos-
pheric oxygen via the airways. It seems unlikely that
hypoxia accounts for the early lung transcriptional
response to Mild PE. Supporting evidence for this con-
clusion is contained in this study. Expression of the hyp-
oxia marker genes Hif1 (hypoxia-inducible factor-1) and
Hyou1 (hypoxia up-regulated 1) were up-regulated in
the 18-h Severe PE treatment group by modest 1.6851-
Table 3 DAVID Functional Annotation Charts, 2-h Severe PE and 18-h Mild PE verses Vehicle
a2-h Severe-PE verses Vehicle 18-h Mild-PE verses Vehicle
Category Term Ct % Dir Fold B&H Ct % Dir Fold B&H
SP_PIR acetylation 78 14.03 UP 1.51 0.009
SP_PIR activator 7 7.29 UP 5.58 0.025
rno00970 Aminoacyl-tRNA biosynthesis 8 1.44 UP 5.56 0.017
rno00330 Arginine and proline metabolism 9 1.62 UP 4.72 0.015
rno05217 Basal cell carcinoma 10 1.11 D 4.28 0.016
IPR011700 Basic leucine zipper 4 4.17 UP 41.80 0.004
IPR004827 Basic-leucine zipper (bZIP) transcription factor 8 8.33 UP 28.54 0.000
SM00338 BRLZ 8 8.33 UP 20.66 0.000
IPR011616 bZIP transcription factor, bZIP-1 4 4.17 UP 25.44 0.015
rno04062 Chemokine signaling pathway 20 3.60 UP 3.25 0.001
SP_PIR chemotaxis 4 4.17 UP 20.78 0.025 11 1.98 UP 10.30 0.000
rno04610 Complement and coagulation cascades 10 1.80 UP 3.97 0.019
SP_PIR cytokine 9 9.38 UP 15.21 0.000 16 2.88 UP 4.88 0.000
rno04060 Cytokine-cytokine receptor interaction 23 4.14 UP 3.25 0.000
SP_PIR disulfide bond 76 13.67 UP 1.43 0.044
SP_PIR DNA binding 6 6.25 UP 7.38 0.028
SP_PIR dna-binding 15 15.63 UP 3.75 0.002
UP_SEQ DNA-binding region: Basic motif 10 10.42 UP 15.44 0.000
UP_SEQ domain: Leucine-zipper 9 9.38 UP 19.96 0.000
rno00982 Drug metabolism 13 1.45 D 3.94 0.004
rno04512 ECM-receptor interaction 14 1.56 D 3.77 0.005
PIRSF001719 fos transforming protein 4 4.17 UP 109.20 0.000
IPR000837 Fos transforming protein 4 4.17 UP 83.59 0.001
rno00480 Glutathione metabolism 9 1.00 D 3.93 0.042
rno00340 Histidine metabolism 7 0.78 D 6.37 0.017
SP_PIR inflammatory response 4 4.17 UP 16.51 0.027 11 1.98 UP 8.18 0.000
rno00980 Metabolism of xenobiotics by cytochrome P450 13 1.45 D 4.73 0.002
rno04621 NOD-like receptor signaling pathway 5 5.21 UP 12.52 0.034 10 1.80 UP 4.49 0.016
SP_PIR nucleus 22 22.92 UP 2.01 0.026
SP_PIR oxidoreductase 42 4.68 D 1.89 0.034
rno05020 Prion diseases 7 1.26 UP 5.56 0.028
SP_PIR ribosome biogenesis 7 1.26 UP 8.85 0.007
SM00199 SCY 5 5.21 UP 18.26 0.003 10 1.80 UP 8.76 0.000
IPR001811 Small chemokine, interleukin-8-like 5 5.21 UP 25.22 0.002 10 1.80 UP 8.70 0.001
SP_PIR Transcription 14 14.58 UP 3.23 0.009
SP_PIR transcription regulation 14 14.58 UP 3.48 0.006
Functional annotations significantly over-represented in the lists of up-regulated and down-regulated genes during 2-h Severe PE and 18-h Mild PE. Annotations
unique to both treatments are highlighted in bold Italics; unique annotations are in standard font. Keys are the same as in Table 1. aNo 2-h DOWN Annotations
meet B&H < 0.05
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fold and 3.3772-fold levels, respectively (Additional file
2E; lines 6823 and 4267) but neither was up-regulated
by the Mild PE treatment. These results discount a role
for lung hypoxia following PE, at least at the Mild PE
dose of microspheres.
It seems reasonable that some hemostatic disruption re-
lated to ischemia, but not based on transfer of oxygen and/
or nutrients to lung tissue, was responsible for the effects
on gene expression seen in this study. An intriguing possi-
bility is “stop-of-flow”, a phenomenon introduced by Fisher
and co-workers [29–34]. Vascular endothelium are adapted
to conditions of flow in vivo, with cell membranes and cy-
toskeletons aligning along the axis of blood flow. This can
also be mimicked in vitro by applying flow over cells which
were initially cultured in the absence of flow [33]. Endothe-
lial cells grown in the absence of flow show a random
organization of membranes and cytoskeletal structures, but
when a laminar flow is applied to these cultures the cells
adopt a flow-axial organization similar to that seen in vivo.
Importantly, when flow is discontinued on cultures of
flow-adapted cells, several signaling pathways are activated,
including a signaling cascade mediated by NADPH oxidase
2-dependent ROS production (reactive oxygen species; 32).
This also occurs in vivo in isolated perfused lungs sub-
jected to ischemia. Pulmonary endothelial membrane
depolarization, H2O2 production and increased intracellu-
lar Ca2+ have been observed within 10–15 s after the onset
of non-hypoxic ischemia [34]. This rapid response can
easily accommodate the increased gene expression seen in
rats with 2-h Mild PE. Several comprehensive reviews have
been published on the proposed general applicability of the
“stop-of-flow” mechanism to explain the pathophysiology
of tissue ischemia, including the ischemia associated with
PE [35–37].
Finally, 18-h Severe PE resulted in the over-expression
of genes present in several gene annotations related to
steroid, lipid, and/or cholesterol biosynthesis. These re-
sults are consistent with a recent report that bile acids
accumulate in lung tissues suffering from pulmonary ar-
tery hypertension; bile acids are downstream of choles-
terol biosynthesis [38]. They are also consistent with
numerous studies that have demonstrated the efficacy
HMG-CoA reductase inhibitors (statins) in reducing the
severity of pulmonary hypertension in both chronic hyp-
oxia and monocrotaline animal models [39–44], al-
though contradictory results have also been observed
[45]. Several mechanisms, un-linked to the known effect
of statin drugs on reducing serum cholesterol, have been
proposed to explain the efficacy of statins for PH but a
clear explanation is premature.
Clinical relevance includes the potential hypothesis
that PE without PH may produce inflammatory changes
in the lung, leading to lung-initiated, systemic inflamma-
tion, and increased risk of ongoing hypercoagulability
and clot recurrence [13, 14]. Humans with PE have 4–7
fold increases in circulating biomarkers of inflammation
Table 4 Steroid/Sterol Biosynthesis Genes
Symbol Fold Dir. Gene Name
CH25H 6.84 UP Cholesterol 25-hydroxylase
DHCR24 2.33 UP 24-dehydrocholesterol reductase
DHCR7 2.15 UP 7-dehydrocholesterol reductase
FDFT1 1.56a UP Farnesyl diphosphate farnesyl transferase 1
FDPS 1.89 UP Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase,
dimethylallyltranstransferase, geranyltranstransferase)
HMGCR 2.11a UP 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
HMGCS1 3.74 UP 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)
HSD17B12 3.03 UP Hydroxysteroid (17-beta) dehydrogenase 12
HSD17B7 4.33 UP Hydroxysteroid (17-beta) dehydrogenase 7
IDI1 8.61 UP Isopentenyl-diphosphate delta isomerase 1
MVD 3.34 UP Mevalonate (diphospho) decarboxylase
NSDHL 1.84 UP NAD(P) dependent steroid dehydrogenase-like
SC4MOL 1.9 UP Sterol-C4-methyl oxidase-like
SC5DL 2.33a UP Sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, S. cerevisiae)
SOAT1 2.59a UP Sterol O-acyltransferase 1
SQLE 3.26 UP Squalene epoxidase
Steroid and sterol biosynthesis genes altered in the 18-h Severe PE treatment group. The three steroid/sterol annotations from Table 2 contained a total of 16
unique genes. All of the original DAVID downloads of PE-regulated annotations shown in Tables 1 and 2 and included lists of the genes within an annotation that
were also altered by PE. These gene lists were very large and were not included in Tables 1, 2 and 3 to save space. The three annotations “SP_PIR Steroid biosynthesis”,
“rno00100 Steroid biosynthesis” and “SP_PIR Sterol biosynthesis” contained 13, 9 and 11 genes, respectively. The 16 genes shown above represent the total unique
genes. “Dir”, direction of fold-change. aAverage fold-change of 2 or more probesets for a single gene
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(tumor necrosis factor, C reactive protein, interleukin 6
and myeloperoxidase) that return to near normal levels
after three months of treatment [46, 47]. Approximately
1/3 of patients with PE have sustained unresolved perfu-
sion defects after PE diagnosis [48]. A growing body of
literature has found that treatment with statins reduce
circulating concentrations of IL-6, CRP and monocyte
chemoattractant protein 1, and may reduce VTE recur-
rence [49]. Our data suggest persistent pulmonary vas-
cular occlusion, even with minimal or absent PH may
cause lung inflammation with PE. These data may imply
that early re-canalization should decrease this inflamma-
tory response. This is a prime goal of “Pulmonary Em-
bolism Response Teams” being organized at many sites
around the US with the goal of rapid recanalization of
pulmonary arteries in patients with severe PE [50].
Conclusion
This is the first report to show that mild pulmonary embol-
ism produces profound alteration in gene transcription in
lungs, primarily in terms of increased expression of genes
encoding inflammatory chemokines and cytokines and
cholesterol synthesis. These data show that unresolved pul-
monary vascular occlusion produces ongoing lung inflam-
mation even in the absence of elevated pulmonary arterial
pressures. Translational implications include the adverse ef-
fects of ongoing inflammation from unresolved pulmonary
vascular occlusions, and conversely, possible benefit of
treating PE to an endpoint of complete clot resolution.
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